Home / Guidelines

Guidelines

FDA releases new guidance to speed up generics approvals

The US Food and Drug Administration (FDA) has released a guidance document that aims to reduce the time that it takes for safe and effective generics to reach the market.

FDA releases product-specific guidance to increase generics competition

The US Food and Drug Administration (FDA) has issued 54 product-specific draft guidances with the aim of promoting access to generics and increasing drug price competition.

WHO asks for comments on new biosimilar Q&A

As part of plans to provide additional clarification of its 2009 guidelines on the evaluation of biosimilars, the World Health Organization (WHO) has drafted a new document providing answers to questions that regulators have posed over the past eight years.

FDA issues final guidance on ANDA/PAS amendments

The US Food and Drug Administration (FDA) has issued final guidance outlining the agency’s review goals for amendments to abbreviated new drug applications (ANDAs) and prior approval supplements (PASs) under Generic Drug User Fee Amendments II (GDUFA II).

FDA issues guidance for labelling biologicals and biosimilars

The US Food and Drug Administration (FDA) has issued two new guidance documents that provide recommendations to industry on labelling requirements for biologicals and biosimilars.

FDA issues final guidance on biosimilar user fees

The US Food and Drug Administration (FDA) has issued final guidance on the agency’s Biosimilar User Fee Act (BsUFA) II fee structure finalizing the changes introduced since BsUFA I.

FDA withdraws biosimilar statistical guidance

The US Food and Drug Administration (FDA) announced on 21 June 2018 that it had withdrawn the draft guidance on analytical studies of biosimilars. The agency does, however, plan to issue an amended version that ‘will reflect state-of-the-art techniques in the evaluation of analytical data’ and give sponsors ‘appropriate flexibility’.

FDA issues draft guidance on biosimilar meetings

The US Food and Drug Administration (FDA) has issued new draft guidance that provides recommendations to industry on formal meetings between FDA and sponsors or applicants relating to the development and review of biosimilar or interchangeable biological products.

FDA issues guidance on quality considerations for inhaled drugs

The US Food and Drug Administration (FDA) has issued draft guidance on quality considerations for inhaled drugs.

Global guidelines for biosimilars

Last update: 15 June 2018

The public health arm of the United Nations is World Health Organisation (WHO).

WHO, via its biological standardisation programme, develops guidelines and recommendations on the production and control of biological products and technologies.